Biodesix (NASDAQ:BDSX) Director Buys $337,075.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 13,900 shares of the stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $24.25 per share, with a total value of $337,075.00. Following the completion of the transaction, the director owned 527,110 shares in the company, valued at approximately $12,782,417.50. This represents a 2.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Price Performance

Shares of NASDAQ BDSX opened at $24.00 on Friday. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. Biodesix, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $25.52. The firm has a market capitalization of $253.20 million, a PE ratio of -7.57 and a beta of 0.56. The stock’s 50-day simple moving average is $20.50 and its 200-day simple moving average is $16.19.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.19. The firm had revenue of $26.86 million during the quarter, compared to analysts’ expectations of $26.03 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. As a group, equities research analysts forecast that Biodesix, Inc. will post -2.68 EPS for the current fiscal year.

Institutional Trading of Biodesix

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP acquired a new stake in Biodesix during the 2nd quarter worth $112,000. BlackRock Inc. purchased a new position in Biodesix during the 2nd quarter worth $970,000. AIGH Capital Management LLC acquired a new position in Biodesix in the second quarter valued at $15,296,000. GSA Capital Partners LLP acquired a new position in Biodesix in the second quarter valued at $1,060,000. Finally, Walleye Capital LLC purchased a new stake in shares of Biodesix in the second quarter valued at about $1,679,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on BDSX shares. Roth Capital started coverage on shares of Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Canaccord Genuity Group lifted their price target on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price target (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.